Early observations

Following the strategic partnership agreement signed in autumn 2025 between OneTwo Analytics and Metabolic (formerly GluCare Health) in the United Arab Emirates, the platform has now been implemented in clinical practice within Metabolic’s operations.

Metabolic is a pioneer in hybrid care, applying a data-driven model for the management of metabolic diseases that combines continuous data collection with active patient engagement. Through this collaboration, OneTwo Analytics delivers automated analysis of CGM data, supporting Metabolic’s efforts to enhance diabetes care and expand access to treatment for a larger patient population.

From streams of CGM data to clinical clarity

The challenge in metabolic care is rarely data collection. It is turning that data into clear next steps fast enough for day-to-day clinical decision-making. OneTwo Analytics empowers the Metabolic team to focus on what matters, align quickly on priorities, and communicate more clearly with patients between visits. That is what continuous care should feel like.

After the initial implementation period, Metabolic has shared its early experiences of how the platform has influenced clinical workflows, data visibility, and communication with patients in day-to-day clinical practice.

High quality onboarding and support

Metabolic describes the quality of onboarding, training, and ongoing support as very high. Collaboration around integration and further development is described as responsive, with quick feedback on questions and feature requests.

Improved structure in data analysis

One of the most noticeable changes relates to how CGM data is analyzed in clinical practice. Previously, identifying patterns and deviations required a more manual review of daily glucose curves. Users of Insights at Metabolic report that it is now easier to quickly identify problem areas in glucose control. Features that are particularly appreciated include the overview of average glucose before, during, and after meals, which provides a quick understanding of the patient’s glucose patterns.

Support for a continuous care model

While still early in its evaluation of potential effects on patient engagement or clinical outcomes, the clinic reports that the Insights report feature, provides a comprehensive overview of patient data and that the platform supports their model of continuous follow-up between visits.

Patient communication and report structure

The use of color-coded visualizations and a clearer presentation of key metrics, including mean glucose and glucose variability, have also contributed to more structured patient communication. The result is a conversation grounded in shared understanding, not just numbers.

Overall assessment

The overall experience of OneTwo Analytics as a clinical tool has been well received. Metabolic states that they would recommend the system both to colleagues and to patients. As OneTwo Analytics continues to expand its platform and services beyond CGM, we aim to evolve and grow the platform alongside Metabolic. A more comprehensive case study describing the collaboration is planned to be published at a later stage.

Together with the Beat Diabetes Foundation, we organized the seminar "Shaping the Future of AI in Diabetes Care" at The Park, Forskaren in Stockholm. We gathered leading researchers, entrepreneurs, healthcare professionals, people with diabetes, and experts in AI and health to discuss the opportunities and challenges of implementing AI in diabetes care. It was an inspiring afternoon filled with insightful presentations and discussions, where we explored how AI can help solve many of the challenges that diabetes care faces today.

The Beat Diabetes Foundation has for many years worked to raise awareness about diabetes and contribute to research and development in the field. During the seminar, the foundation announced that they are making a donation to OneTwo Analytics, with the purpose to promote innovation and the development of AI in diabetes care.

At OneTwo Analytics, we are deeply grateful for Beat Diabetes Foundation's generous support and the trust placed in us to carry their vision forward. Through this contribution, their mission will live on. We will continue to champion their ideals, pushing the boundaries and driving innovation to improve care and quality of life for people living with diabetes.

We are proud to announce that OneTwo Analytics in Sweden and GluCare.Health/metabolic in the UAE have signed a strategic agreement!

GluCare.Health, a pioneer in hybrid care models, is transforming metabolic health management by integrating continuous data streams and proactive patient engagement.

OneTwo Analytics specializes in advanced AI-driven data analysis, helping healthcare providers unlock deeper insights and improve patient outcomes.

Through this collaboration, OneTwo Analytics will deliver AI-based analysis of continuous glucose data, enabling GluCare to enhance care delivery and serve more patients with precision and scale. The SaaS services are being commissioned immediately, starting with approximately 1,200 patients, across diabetes, prediabetes and obesity, with ambitious plans to expand further in the coming year.

Ihsan Almarzooqi, co-founder and MD of GluCare.Health, shares:

"Partnering with OneTwo allows us to strengthen our mission of redefining chronic disease care. As the largest regional users of continuous glucose monitors, by harnessing AI-powered insights, we can support our clinicians and patients even more effectively - and scale this model of care to reach thousands more."

Lars Cederblad, CEO of OneTwo Analytics, adds:

"We are so happy to work with this very progressive clinic at the forefront of applying digital devices and services to improve diabetes care."

This partnership marks an exciting step forward in using technology and AI to make a real difference in the lives of people living with metabolic health issues.

Our co-founder and CMO, Professor Per-Ola Carlsson, is a leading researcher in type 1 diabetes. His groundbreaking research investigates the potential of genetically modified, hypoimmune insulin-producing cells from the islets of Langerhans as a cure for type 1 diabetes. Here’s what he has to say about his research:

"We have shown that genetically modified beta cells can survive and produce insulin in people with type 1 diabetes – without the need for immunosuppressive treatment. These early results are a significant step forward in our research towards a cure."

While the search for a cure continues, Professor Carlsson is also committed to improving diabetes care:

"My long-term goal is to contribute to a cure for type 1 diabetes, but in the meantime, I aim to enhance the clinical management of diabetes and the daily lives of everyone living with diabetes by developing digital solutions that can automate the interpretation of diabetes data."

Read more about the study here.